ATE445408T1 - Verwendung von prolactin in der prophylaktischen krebstherapie - Google Patents

Verwendung von prolactin in der prophylaktischen krebstherapie

Info

Publication number
ATE445408T1
ATE445408T1 AT06826240T AT06826240T ATE445408T1 AT E445408 T1 ATE445408 T1 AT E445408T1 AT 06826240 T AT06826240 T AT 06826240T AT 06826240 T AT06826240 T AT 06826240T AT E445408 T1 ATE445408 T1 AT E445408T1
Authority
AT
Austria
Prior art keywords
prolactin
cancer therapy
prophylactic cancer
prophylactic
compositions
Prior art date
Application number
AT06826240T
Other languages
English (en)
Inventor
Wen Chen
Original Assignee
Ghc Res Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghc Res Dev Corp filed Critical Ghc Res Dev Corp
Application granted granted Critical
Publication of ATE445408T1 publication Critical patent/ATE445408T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2257—Prolactin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06826240T 2005-10-20 2006-10-19 Verwendung von prolactin in der prophylaktischen krebstherapie ATE445408T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72829705P 2005-10-20 2005-10-20
US76389206P 2006-02-01 2006-02-01
PCT/US2006/040806 WO2007047803A2 (en) 2005-10-20 2006-10-19 Use of prolactin in the prophylactic treatment of cancer

Publications (1)

Publication Number Publication Date
ATE445408T1 true ATE445408T1 (de) 2009-10-15

Family

ID=37963261

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06826240T ATE445408T1 (de) 2005-10-20 2006-10-19 Verwendung von prolactin in der prophylaktischen krebstherapie

Country Status (6)

Country Link
US (1) US20100041598A1 (de)
EP (1) EP1959985B1 (de)
AT (1) ATE445408T1 (de)
CA (1) CA2626785A1 (de)
DE (1) DE602006009840D1 (de)
WO (1) WO2007047803A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784422B2 (en) * 2000-02-01 2006-03-30 Stevia Aps A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
WO2011097268A1 (en) * 2010-02-03 2011-08-11 Orbis Health Solutions Llc Method for sensitizing cells to cancer therapy
EP2526961A1 (de) * 2011-05-26 2012-11-28 Mario Sargentini Behandlung oder Linderung einige neuroendokrine Erkrankungen bei männlichen mit Hilfe von Prolaktin
CN114222582A (zh) * 2019-07-09 2022-03-22 横向知识产权私人有限公司 肽及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
WO1999058097A2 (en) * 1998-05-12 1999-11-18 Greenville Hospital System Use of anti-prolactin agents to treat proliferative conditions
CA2499972A1 (en) * 2002-09-25 2004-04-08 Garvan Institute Of Medical Research Method for inducing mammary epithelial cell differentiation

Also Published As

Publication number Publication date
WO2007047803A3 (en) 2007-09-07
DE602006009840D1 (de) 2009-11-26
EP1959985B1 (de) 2009-10-14
CA2626785A1 (en) 2007-04-26
WO2007047803A2 (en) 2007-04-26
EP1959985A2 (de) 2008-08-27
US20100041598A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
IL258880A (en) Compounds of diarylhydantoin
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200701995A1 (ru) Способы уменьшения кальцификации
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
UA89226C2 (en) Imidazole compounds
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
NO20055741L (no) Nye kjemiske forbindelser
TW200716088A (en) Formulations and methods for treating amyloidosis
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
EA200702136A1 (ru) Композиции станнсопорфина и их применение
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
UA29209U (ru) Способ хирургического лечения рака молочной железы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties